GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Institutional Ownership

SAB Biotherapeutics (SAB Biotherapeutics) Institutional Ownership : 2.47% (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SAB Biotherapeutics's institutional ownership is 2.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SAB Biotherapeutics's Insider Ownership is 21.45%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SAB Biotherapeutics's Float Percentage Of Total Shares Outstanding is 75.68%.


SAB Biotherapeutics Institutional Ownership Historical Data

The historical data trend for SAB Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Institutional Ownership Chart

SAB Biotherapeutics Historical Data

The historical data trend for SAB Biotherapeutics can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 2.99 3.02 4.16 2.95 2.33 2.33 1.58 2.47 2.47 2.47

SAB Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2100 East 54th Street North, Sioux Falls, SD, USA, 57104
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Executives
Eddie Joe Sullivan director, 10 percent owner, officer: Chief Executive Officer 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King officer: CHIEF FINANCIAL OFFICER 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich director, officer: Executive Chairman ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton director, 10 percent owner 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova officer: Chief Medical Officer RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137